Pharmaceutical manufacturing facility
Phillips-Medisize is constructing a pharmaceutical manufacturing facility in Hudson, Wisconsin, US.
Estimated to cost $40m, the facility will be used for innovation, development and manufacturing of pharmaceutical and medical devices solutions. It will help expand the company’s end-to-end offerings for its customers.
The ground-breaking ceremony for the project took place in February 2019, while the construction is anticipated to be completed by mid-2020.
The facility will employ approximately 250 people when operational.
The manufacturing facility is being built on a 34-acre undeveloped site in the St. Croix Meadows redevelopment in Hudson, Wisconsin.
The site was purchased by Phillips-Medisize in October 2018 to expand its high-tech manufacturing operations regulated by the US Food and Drug Administration (FDA) in Wisconsin.
Spanning approximately 132 acres, the St. Croix Meadows site is a mixed-use development site that will include corporate offices, hotels, a retail area, a hi-tech flex space, a conference space, housing and a sports complex.
The pharmaceutical manufacturing facility will occupy a floor area of 230,000ft² in the St. Croix Meadows site.
The facility is FDA-registered and will be outfitted with cleanrooms and state-of-the-art equipment to develop and manufacture FDA-regulated products.
The facility will be in compliance with current good manufacturing practice (cGMP) to follow the quality production standards in the manufacturing process.
The facility is designed with 60,000ft² of architectural insulated precast and solid precast wall panels. The panels feature light colour mix having an etched finish, recessed abrasive blast and bands of form liner to create the desired visual effects.
Molin Concrete Products was contracted to provide architectural precast wall panels for the Phillips-Medisize pharmaceutical manufacturing facility.
Molin Concrete provided shop drawings and engineering services for the facility during the design development phase and assisted the design team in finalising the drawings for the construction.
The company coordinated with the general contractor Market and Johnson for site access, logistics and safety, as well as for installation plans. Market and Johnson partnered with the US Department of Labour in May 2019 to promote the health and safety of the workers during the construction phase.
River Valley Architects was selected to provide architectural design services, while Ericksen Roed & Associates provides structural engineering services for the facility.
Phillips-Medisize provides end-to-end services through an integrated model. It implements the same quality management system (QMS) to ensure the quality of all of its services, a practice that reduces the time consumption at every stage and provides maximum flexibility.
The company has two technology accelerators namely drug delivery device technology accelerators and connected health technology accelerators.
The drug delivery device technology accelerators assist the customers in designing and providing customised drug delivery device according to the desired technology requirement.
The technology accelerators for connected health embed connectivity capabilities to the system. A connected health system contains three main elements, which include a connected device and sensors, digital interface, and a Cloud database platform.
Phillips-Medisize is an indirect subsidiary of Molex. The company provides end-to-end solutions to pharmaceutical, diagnostics and medical devices markets.
The company’s offerings are front-end innovation, design and development, manufacturing development, clinical and commercial manufacturing, as well as post-launch services including Connected Health app and data services.
Headquartered in Wisconsin, US, the company employs more than 5,500 people across 26 manufacturing sites worldwide.
The Columbus Innovation District is a proposed healthcare and technology hub within the Ohio State University in the state of…
Rocket Pharmaceuticals will build a new research and development (R&D) and manufacturing facility in Cranbury, New Jersey, US to support…
BioNTech’s manufacturing site in Marburg, Germany, will be used for the production of its Covid-19 vaccine candidate, BNT162. Based on…